Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (VENICE II)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Jul 2018
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms VENICE II
- Sponsors AbbVie
- 18 Jul 2018 Romania was one of the planned locations for this trial.
- 18 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2018 Planned end date changed from 13 Dec 2022 to 27 Jun 2022.